Now showing items 2354-2373 of 4635

    • Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a gene expression profile 

      Jenner, RG; Maillard, K; Cattini, N; Weiss, RA; Boshoff, C; Wooster, R; Kellam, P (2003-09-02)
      Kaposi’s sarcoma-associated herpesvirus is associated with three human tumors: Kaposi’s sarcoma, and the B cell lymphomas, plasmablastic lymphoma associated with multicentric Castleman’s disease, and primary effusion ...
    • Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study 

      Berney, DM; Gopalan, A; Kudahetti, S; Fisher, G; Ambroisine, L; Foster, CS; Reuter, V; Eastham, J; Moller, H; Kattan, MW; Gerald, W; Cooper, C; Scardino, P; Cuzick, J; Grp, T-AP (NATURE PUBLISHING GROUP, 2009-03-17)
      Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a ...
    • Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

      Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-06)
      PURPOSE:To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
    • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 

      Ellis, MJ; Suman, VJ; Hoog, J; Goncalves, R; Sanati, S; Creighton, CJ; DeSchryver, K; Crouch, E; Brink, A; Watson, M; Luo, J; Tao, Y; Barnes, M; Dowsett, M; Budd, GT; Winer, E; Silverman, P; Esserman, L; Carey, L; Ma, CX; Unzeitig, G; Pluard, T; Whitworth, P; Babiera, G; Guenther, JM; Dayao, Z; Ota, D; Leitch, M; Olson, JA; Allred, DC; Hunt, K (2017-04)
      Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 ...
    • Kinetic energy of He atoms in liquid He-4-He-3 mixtures 

      Senesi, R; Andreani, C; Fielding, AL; Mayers, J; Stirling, WG (AMER PHYSICAL SOC, 2003-12)
      Deep inelastic neutron scattering measurements on liquid He-3-He-4 mixtures in the normal phase have been performed on the VESUVIO spectrometer at the ISIS pulsed neutron source at exchanged wave vectors of about qsimilar ...
    • Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72. 

      Pettinger, J; Carter, M; Jones, K; Cheeseman, MD (2019-12-06)
      The covalent inhibition mechanism of action, which overcomes competition with high-affinity, high-abundance substrates of challenging protein targets, can deliver effective chemical probes and drugs. The success of this ...
    • Klotho and the Treatment of Human Malignancies. 

      Sachdeva, A; Gouge, J; Kontovounisios, C; Nikolaou, S; Ashworth, A; Lim, K; Chong, I (2020-06-23)
      Klotho was first discovered as an anti-ageing protein linked to a number of age-related disease processes, including cardiovascular, renal, musculoskeletal, and neurodegenerative conditions. Emerging research has also ...
    • Klotho: A Major Shareholder in Vascular Aging Enterprises. 

      Lim, K; Halim, A; Lu, T-S; Ashworth, A; Chong, I (2019-09-19)
      Accelerated vascular aging is a condition that occurs as a complication of several highly prevalent inflammatory conditions such as chronic kidney disease, cancer, HIV infection and diabetes. Age-associated vascular ...
    • Known drug space as a metric in exploring the boundaries of drug-like chemical space 

      Mirza, Amin (2009)
      In this work, marketed drug compounds (or known drug space) were used as a metric to test the principles of eliminating parent structures of the nitrenium ion (aryl-amine/nitro compounds) as well as sulphur and halogen ...
    • KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. 

      Sclafani, F; Chau, I; Cunningham, D; Hahne, JC; Vlachogiannis, G; Eltahir, Z; Lampis, A; Braconi, C; Kalaitzaki, E; De Castro, DG; Wotherspoon, A; Capdevila, J; Glimelius, B; Tarazona, N; Begum, R; Lote, H; Hulkki Wilson, S; Mentrasti, G; Brown, G; Tait, D; Oates, J; Valeri, N (2018-01-23)
      There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples ...
    • KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. 

      Bery, N; Legg, S; Debreczeni, J; Breed, J; Embrey, K; Stubbs, C; Kolasinska-Zwierz, P; Barrett, N; Marwood, R; Watson, J; Tart, J; Overman, R; Miller, A; Phillips, C; Minter, R; Rabbitts, TH (2019-06-13)
      Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that ...
    • L-serine in disease and development 

      De Koning, TJ; Snell, K; Duran, M; Berger, R; Poll-The, BT; Surtees, R (PORTLAND PRESS LTD, 2003-05-01)
      The amino acid L-serine, one of the so-called non-essential amino acids, plays a central role in cellular proliferation. L-Serine is the predominant source of one-carbon groups for the de novo synthesis of purine nucleotides ...
    • Labelled chemical probes for demonstrating direct target engagement in living systems. 

      Prevet, H; Collins, I (2019-05)
      Demonstrating target engagement in living systems can help drive successful drug discovery. Target engagement and occupancy studies in cells confirm direct binding of a ligand to its intended target protein and provide the ...
    • Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. 

      Saunders, CN; Cornish, AJ; Kinnersley, B; Law, PJ; Claus, EB; Il'yasova, D; Schildkraut, J; Barnholtz-Sloan, JS; Olson, SH; Bernstein, JL; Lai, RK; Chanock, S; Rajaraman, P; Johansen, C; Jenkins, RB; Melin, BS; Wrensch, MR; Sanson, M; Bondy, ML; Houlston, RS (2020-02)
      Background The etiological basis of glioma is poorly understood. We have used genetic markers in a Mendelian randomization (MR) framework to examine if lifestyle, cardiometabolic, and inflammatory factors influence the ...
    • Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. 

      Tokaca, N; Wotherspoon, A; Nicholson, AG; Fotiadis, N; Thompson, L; Popat, S (2017-09)
      Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed ...
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

      Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, S-M; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GKJ; Jang, SJ; Jones, DR; Kim, H-Y; King, TA; Krishnamurthy, S; Lee, HJ; Lee, J-Y; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BKT; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JWM; Børresen-Dale, A-L; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
      We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
    • Landscape of the Plasmodium Interactome Reveals Both Conserved and Species-Specific Functionality. 

      Hillier, C; Pardo, M; Yu, L; Bushell, E; Sanderson, T; Metcalf, T; Herd, C; Anar, B; Rayner, JC; Billker, O; Choudhary, JS (2019-08)
      Malaria represents a major global health issue, and the identification of new intervention targets remains an urgent priority. This search is hampered by more than one-third of the genes of malaria-causing Plasmodium ...
    • Landscape of transcriptomic interactions between breast cancer and its microenvironment. 

      Fox, NS; Haider, S; Harris, AL; Boutros, PC (2019-07-15)
      Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, ...
    • Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. 

      Georgopoulou, D; Callari, M; Rueda, OM; Shea, A; Martin, A; Giovannetti, A; Qosaj, F; Dariush, A; Chin, S-F; Carnevalli, LS; Provenzano, E; Greenwood, W; Lerda, G; Esmaeilishirazifard, E; O'Reilly, M; Serra, V; Bressan, D; IMAXT Consortium; Mills, GB; Ali, HR; Cosulich, SS; Hannon, GJ; Bruna, A; Caldas, C (2021-03-31)
      The heterogeneity of breast cancer plays a major role in drug response and resistance and has been extensively characterized at the genomic level. Here, a single-cell breast cancer mass cytometry (BCMC) panel is optimized ...